A certain class of oral drugs used to treat type 2 diabetes can double the risk of heart failure in patients, warn a group of group of researchers led by an Indian origin researcher.
Sonal Singh, assistant professor of internal medicine, and Curt D. Furberg, M.D., Ph.D., professor of public health sciences, from Wake Forest University School of Medicine faculty members have said that thiazolidinediones can exacerbate heart attack risk.
"We strongly recommend restrictions in the use of thiazolidinediones (the class of drugs) and question the rationale for leaving rosiglitazone on the market," wrote experts.
"At this time, justification for use of thiazolidinediones is very weak to non-existent," they added.
Rosiglitazone
This medication is a thiazolidinedione antidiabetic, prescribed for type 2 diabetes along with diet and exercise.
This medication is a thiazolidinedione antidiabetic, prescribed for type 2 diabetes along with diet and exercise.
Heart disease and high blood pressure "represent conditions that are major precursors of congestive heart failure."
Advertisement
Pioglitazone Hydrochloride
Pioglitazone hydrochloride is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type II diabetes - non-insulin dependent diabetes mellitus, NIDDM.
Pioglitazone hydrochloride is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type II diabetes - non-insulin dependent diabetes mellitus, NIDDM.
They said that results from three large randomized clinical trials earlier failed to demonstrate that intensive control of blood sugar reduces mortality or events from cardiovascular disease in patients with type 2 diabetes.
Advertisement
SRM
